Month: September 2016
-
Challenge Seeks Gastrointestinal Toxicity Test Methods
A challenge competition on InnoCentive sponsored by AstraZeneca is looking for new lab tests for toxic effects of drugs on the gastrointestinal tract.
-
Gene Silencing Treatments Licensed for Heart Disease
Biopharmaceutical company Amgen is acquiring the rights to a technology that stops the actions of inherited genes associated with a leading type of heart disease.
-
Material Developed for 3-D Printed Bone
A synthetic material called hyperelastic bone is shown to produce replacement bone with a 3-D printer and in lab animals supports the growth of new bone without causing an immune response.
-
Six Top Tech Graduate Degrees to Help Boost Your Career
The truth is that it’s easy to update your skills and career possibilities if you think about going back to school for your master’s degree.
-
FDA Clears Artificial Pancreas System for Type 1 Diabetes
The Food and Drug Administration cleared for sale a system that automatically monitors blood glucose and maintains basic insulin levels in people with type 1 diabetes.
-
Harvard Spin-Off to Sequence, Visualize RNA in Tissue
A new spin-off enterprise from Harvard University is commercializing technology that enables sequencing and imaging of genetic transcriptions of cells in their original tissue.
-
Spinal Cord Injury Rehab Device in Development
A robotic device to improve the balance of people going through rehabilitation after spinal cord injury is being developed by an engineering-medical team from Columbia University and University of Louisville.
-
Trial Shows Engineered T-Cells Can Stop Lymphoma
Early results of a clinical trial show an individual’s own immune system cells altered to attack non-Hodgkin lymphoma can cause a partial or complete response in a large percentage of patients.
-
DoD Grant Funds Exosome Manufacturing Process
A biotechnology company is receiving a Department of Defense grant to develop a commercial-scale manufacturing process for exosomes, tiny bubbles that deliver drugs to cells in the body.
-
Spin-Off Companies to Develop Chronic Disease Therapies
Two new spin-off enterprises are being created to develop gut-based treatments for chronic diseases using technologies from synthetic biology company Intrexon Corporation.